| Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. | |
| | |
MedLine Citation:
|
PMID: 16956836 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells. |
| | |
Authors:
|
Jan Samuelsson; Manuel Mutschler; Gunnar Birgegård; Poul Gram-Hansen; Magnus Björkholm; Heike L Pahl |
Related Documents
:
|
17075396 - Increased polymorphism in the hr-1 gp41 env gene encoding the enfuvirtide (t-20) target... 18398736 - Jak2 v617f patients with essential thrombocythemia present with clinical features of po... 21541226 - Detrusor arreflexia as an end stage of neurogenic bladder in ham/tsp? 20413436 - Correlation of kidney function, volume and imaging findings, and pkhd1 mutations in 73 ... 17720726 - Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropath... 17075396 - Increased polymorphism in the hr-1 gp41 env gene encoding the enfuvirtide (t-20) target... |
Publication Detail:
|
Type: Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Haematologica Volume: 91 ISSN: 1592-8721 ISO Abbreviation: Haematologica Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-09-07 Completed Date: 2006-10-24 Revised Date: 2012-06-05 |
Medline Journal Info:
|
Nlm Unique ID: 0417435 Medline TA: Haematologica Country: Italy |
Other Details:
|
Languages: eng Pagination: 1281-2 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Female Humans Interferon-alpha / therapeutic use* Janus Kinase 2 Male Middle Aged Mutation Myeloproliferative Disorders / drug therapy*, enzymology, genetics* Polycythemia Vera / drug therapy, enzymology, genetics Polyethylene Glycols Protein-Tyrosine Kinases / genetics* Proto-Oncogene Proteins / genetics* Recombinant Proteins Thrombocythemia, Essential / drug therapy, enzymology, genetics Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Interferon-alpha; 0/Polyethylene Glycols; 0/Proto-Oncogene Proteins; 0/Recombinant Proteins; 0/peginterferon alfa-2b; 99210-65-8/interferon alfa-2b; EC 2.7.10.1/Janus Kinase 2; EC 2.7.10.1/Protein-Tyrosine Kinases; EC 2.7.10.2/JAK2 protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Molecular characterization of thalassemia intermedia in Indians.
Next Document: A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.